[The attack of acute porphyria].
The attack of acute porphyria Based on in silico evidence of pharmacokinetic, pharmacodynamic, and physiologic properties, have approximately 1 300 medicinal drugs been assessed with regard to the specific risk to carriers of acute porphyria. The classifications have been published in booklet form, together with prophylactic advice to the carriers and suggestions for doctors in charge of their care. The risk-classifications rest on the behavior of the drug in an extended molecular model of the attack of acute porphyria. In this, symptoms are effects of 5-aminolevulinate (ALA) produced in surplus after acceleration of enzyme-deficient heme biosynthesis, taking place during induction of drug-metabolizing cytochromes P450 and triggered by hepatocellular nuclear receptors, activated by the drug. The process is enhanced by glucagon- and sirtuin-dependent molecular processes activated in stress and cellular energy deficit, and enhanced and prolonged by auto-generating ALA.
Porphyria Centre - Laboratory Medicine, Centre for metabolic diseases. Stockholm, Sweden Porphyria Centre - Laboratory Medicine, Centre for metabolic diseases. Stockholm, Sweden.
Stig
S
Thunell
D000465:Algorithms; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D017118:Porphyria, Acute Intermittent / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism